Iceland· IS-EU/1/16/1109/001

Zavicefta

A ceftazidim und beta-lactamase-inhibitor product containing ceftazidimum inn,avibactamum inn natríum, registered in Iceland by Pfizer Ireland Pharmaceuticals. The same ATC class is registered in 10 of our 19 countries.

ATC J01DD52

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedZaviceftaATCJ01DD52REGISTER NO.IS-EU/1/16/1109/001PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Ceftazidim und beta-lactamase-inhibitor is registered in 10 of 19 countries.

Countries holding a registration under ATC J01DD52 (ceftazidim und beta-lactamase-inhibitor), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

Ceftazidim und beta-lactamase-inhibitor · ATC J01DD52

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ceftazidim und beta-lactamase-inhibitor costs, country by country.

Normalised to the WHO defined daily dose (6 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ceftazidim und beta-lactamase-inhibitor · price per daily dose (6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$407.92
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Ceftazidimum INN,Avibactamum INN natríum
Manufacturer
Pfizer Ireland Pharmaceuticals
Country
Iceland (IS)
ATC code
J01DD52
ATC class
Ceftazidim und Beta-Lactamase-Inhibitor
Defined daily dose
6 g, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    183133
    20 ml x10 hgl
    ISK 205606

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d004bdf9-e56d-4262-8866-7e442dd4918b
GET /v1/drugs/d004bdf9-e56d-4262-8866-7e442dd4918b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stofn fyrir innrennslisþykkni, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "J01DD52",
  "marketed": true,
  "strength": "2 g/0,5 g",
  "ma_number": "EU/1/16/1109/001",
  "substance": "Ceftazidimum INN,Avibactamum INN natríum",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "42545"
}

See everything about ceftazidim und beta-lactamase-inhibitor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.